These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 19886148)

  • 1. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates?
    Cannom RR; Kaiser AM; Ault GT; Beart RW; Etzioni DA
    Am Surg; 2009 Oct; 75(10):976-80. PubMed ID: 19886148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trends in surgery for Crohn's disease in the era of infliximab.
    Jones DW; Finlayson SR
    Ann Surg; 2010 Aug; 252(2):307-12. PubMed ID: 20585239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Careful patient selection may improve response rates to infliximab in inflammatory bowel disease.
    Pearce CB; Lawrance IC
    J Gastroenterol Hepatol; 2007 Oct; 22(10):1671-7. PubMed ID: 17845695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality.
    Caspersen S; Elkjaer M; Riis L; Pedersen N; Mortensen C; Jess T; Sarto P; Hansen TS; Wewer V; Bendtsen F; Moesgaard F; Munkholm P;
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1212-7; quiz 1176. PubMed ID: 18848503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
    Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
    Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in hospitalization rates for inflammatory bowel disease in the United States.
    Bewtra M; Su C; Lewis JD
    Clin Gastroenterol Hepatol; 2007 May; 5(5):597-601. PubMed ID: 17382602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume.
    Ananthakrishnan AN; McGinley EL; Binion DG
    Am J Gastroenterol; 2008 Nov; 103(11):2789-98. PubMed ID: 18684184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hospitalization for inflammatory bowel disease in the United States between 1970 and 2004.
    Sonnenberg A
    J Clin Gastroenterol; 2009 Apr; 43(4):297-300. PubMed ID: 18936713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
    Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
    J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients.
    Nguyen GC; Sam J
    Am J Gastroenterol; 2008 Sep; 103(9):2272-80. PubMed ID: 18684186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease.
    Karmiris K; Koutroubakis IE; Xidakis C; Polychronaki M; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):789-94. PubMed ID: 17700265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study.
    Fidder H; Schnitzler F; Ferrante M; Noman M; Katsanos K; Segaert S; Henckaerts L; Van Assche G; Vermeire S; Rutgeerts P
    Gut; 2009 Apr; 58(4):501-8. PubMed ID: 18832524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients.
    Nguyen GC; Kaplan GG; Harris ML; Brant SR
    Am J Gastroenterol; 2008 Jun; 103(6):1443-50. PubMed ID: 18513271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis.
    Longobardi T; Jacobs P; Bernstein CN
    Am J Gastroenterol; 2004 Apr; 99(4):650-5. PubMed ID: 15089897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colectomy rate in acute severe ulcerative colitis in the infliximab era.
    Aratari A; Papi C; Clemente V; Moretti A; Luchetti R; Koch M; Capurso L; Caprilli R
    Dig Liver Dis; 2008 Oct; 40(10):821-6. PubMed ID: 18472316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resource utilization before and during infliximab therapy in patients with inflammatory bowel disease.
    Waters HC; Vanderpoel JE; Nejadnik B; McKenzie RS; Lunacsek OE; Lennert BJ; Goff J; Augustyn DH
    J Med Econ; 2012; 15(1):45-52. PubMed ID: 22023068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.
    Metge CJ; Blanchard JF; Peterson S; Bernstein CN
    Am J Gastroenterol; 2001 Dec; 96(12):3348-55. PubMed ID: 11774948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of chronic inflammatory bowel diseases].
    Lémann M
    Bull Acad Natl Med; 2007 Jun; 191(6):1125-41; discussion 1141. PubMed ID: 18402168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The incidence of inflammatory bowel disease in the pediatric population of Southwestern Ontario.
    Grieci T; Bütter A
    J Pediatr Surg; 2009 May; 44(5):977-80. PubMed ID: 19433182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.